These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The cost-effectiveness of therapeutic drug monitoring. Pippenger CE Ther Drug Monit; 1990 Sep; 12(5):418. PubMed ID: 2127323 [No Abstract] [Full Text] [Related]
7. Toward the operational identification of adverse drug reactions. Karch FE; Lasagna L Clin Pharmacol Ther; 1977 Mar; 21(3):247-54. PubMed ID: 837643 [TBL] [Abstract][Full Text] [Related]
9. Adverse drug reactions: reducing the burden of treatment. Jordan S Nurs Stand; 2007 May 2-8; 21(34):35-41. PubMed ID: 17518073 [TBL] [Abstract][Full Text] [Related]
10. Once is not enough. Gross F Eur J Clin Pharmacol; 1977; 11(5):323-4. PubMed ID: 880970 [No Abstract] [Full Text] [Related]
12. Experience in monitoring drug reactions in outpatients. The Kaiser-Permanente Drug Monitoring System. Friedman GD; Collen MF; Harris LE; Van Brunt EE; Davis LS JAMA; 1971 Aug; 217(5):567-72. PubMed ID: 5109088 [No Abstract] [Full Text] [Related]
13. Promoting adverse drug reaction reporting: comparison of different approaches. Ribeiro-Vaz I; Santos CC; Cruz-Correia R Rev Saude Publica; 2016; 50():14. PubMed ID: 27143614 [TBL] [Abstract][Full Text] [Related]
14. Hospital information systems and the quality of therapeutics. Blaschke TF Methods Inf Med; 1990 Jul; 29(3):163-6. PubMed ID: 2215257 [No Abstract] [Full Text] [Related]
15. Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions. Alagoz O; Durham D; Kasirajan K Pharmacogenomics J; 2016 Apr; 16(2):129-36. PubMed ID: 25987241 [TBL] [Abstract][Full Text] [Related]
16. Causes of severe morbidity/mortality cases. de Julien LF CDA J; 1983 Feb; 11(2):45-8. PubMed ID: 6572112 [No Abstract] [Full Text] [Related]
18. Incidence and costs of adverse drug reactions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting. Dormann H; Muth-Selbach U; Krebs S; Criegee-Rieck M; Tegeder I; Schneider HT; Hahn EG; Levy M; Brune K; Geisslinger G Drug Saf; 2000 Feb; 22(2):161-8. PubMed ID: 10672897 [TBL] [Abstract][Full Text] [Related]
19. The role of cost-effectiveness analysis in the era of pharmacogenomics. Flowers CR; Veenstra D Pharmacoeconomics; 2004; 22(8):481-93. PubMed ID: 15217305 [TBL] [Abstract][Full Text] [Related]
20. An economic evaluation of a laboratory monitoring program for renin-angiotensin system agents. Smith DH; Raebel MA; Chan KA; Johnson ES; Petrik AF; Weiss JR; Yang X; Feldstein A Med Decis Making; 2011; 31(2):315-24. PubMed ID: 21393563 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]